Literature DB >> 17159833

A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults.

Eric E Mast1, Cindy M Weinbaum, Anthony E Fiore, Miriam J Alter, Beth P Bell, Lyn Finelli, Lance E Rodewald, John M Douglas, Robert S Janssen, John W Ward.   

Abstract

Hepatitis B vaccination is the most effective measure to prevent hepatitis B virus (HBV) infection and its consequences, including cirrhosis of the liver, liver cancer, liver failure, and death. In adults, ongoing HBV transmission occurs primarily among unvaccinated persons with behavioral risks for HBV transmission (e.g., heterosexuals with multiple sex partners, injection-drug users [IDUs], and men who have sex with men [MSM]) and among household contacts and sex partners of persons with chronic HBV infection. This report, the second of a two-part statement from the Advisory Committee on Immunization Practices (ACIP), provides updated recommendations to increase hepatitis B vaccination of adults at risk for HBV infection. The first part of the ACIP statement, which provided recommendations for immunization of infants, children, and adolescents, was published previously (CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices [ACIP]. Part 1: immunization of infants, children, and adolescents. MMWR 2005;54[No. RR-16]:1-33). In settings in which a high proportion of adults have risks for HBV infection (e.g., sexually transmitted disease/human immunodeficiency virus testing and treatment facilities, drug-abuse treatment and prevention settings, health-care settings targeting services to IDUs, health-care settings targeting services to MSM, and correctional facilities), ACIP recommends universal hepatitis B vaccination for all unvaccinated adults. In other primary care and specialty medical settings in which adults at risk for HBV infection receive care, health-care providers should inform all patients about the health benefits of vaccination, including risks for HBV infection and persons for whom vaccination is recommended, and vaccinate adults who report risks for HBV infection and any adults requesting protection from HBV infection. To promote vaccination in all settings, health-care providers should implement standing orders to identify adults recommended for hepatitis B vaccination and administer vaccination as part of routine clinical services, not require acknowledgment of an HBV infection risk factor for adults to receive vaccine, and use available reimbursement mechanisms to remove financial barriers to hepatitis B vaccination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17159833

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  271 in total

1.  Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls.

Authors:  Mustafa Erhan Altunöz; Ebubekir Senateş; Atakan Yeşil; Turan Calhan; Ayşe Oya Kurdaş Ovünç
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

2.  Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users.

Authors:  Thanh Q Tran; Carolyn Z Grimes; Dejian Lai; Catherine L Troisi; Lu-Yu Hwang
Journal:  Vaccine       Date:  2011-11-08       Impact factor: 3.641

Review 3.  The management of chronic hepatitis B in Asian Americans.

Authors:  Myron J Tong; Calvin Q Pan; Hie-Won Hann; Kris V Kowdley; Steven-Huy B Han; Albert D Min; Truong-Sinh Leduc
Journal:  Dig Dis Sci       Date:  2011-09-21       Impact factor: 3.199

4.  Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities.

Authors:  Rania A Tohme; Debo Awosika-Olumo; Carrie Nielsen; Salma Khuwaja; Jennifer Scott; Jian Xing; Jan Drobeniuc; Dale J Hu; Cynthia Turner; Toni Wafeeg; Umid Sharapov; Philip R Spradling
Journal:  Vaccine       Date:  2011-10-18       Impact factor: 3.641

5.  Review.

Authors:  Usman Khokhar; Debra Stevens; Linda K Shipton; Daryl T-Y Lau
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-09

6.  Clinical update: hepatitis B.

Authors:  Tram T Tran
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-07

7.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

8.  Hepatitis B testing and vaccination among Vietnamese- and Cambodian-Americans.

Authors:  Scott P Grytdal; Youlian Liao; Roxana Chen; Cheza C Garvin; Dorcas Grigg-Saito; Marjorie Kagawa-Singer; Sidney Liang; Stephen J McPhee; Tung T Nguyen; Jacqueline H Tran; Kathleen M Gallagher
Journal:  J Community Health       Date:  2009-06

9.  Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease.

Authors:  Xin Yue; Carla L Black; Alissa O'Halloran; Peng-Jun Lu; Walter W Williams; Noele P Nelson
Journal:  Vaccine       Date:  2018-02-21       Impact factor: 3.641

10.  Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons.

Authors:  Masako Mizusawa; David C Perlman; David Lucido; Nadim Salomon
Journal:  Int J STD AIDS       Date:  2013-08-29       Impact factor: 1.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.